JP2022529814A5 - - Google Patents
Info
- Publication number
- JP2022529814A5 JP2022529814A5 JP2021562854A JP2021562854A JP2022529814A5 JP 2022529814 A5 JP2022529814 A5 JP 2022529814A5 JP 2021562854 A JP2021562854 A JP 2021562854A JP 2021562854 A JP2021562854 A JP 2021562854A JP 2022529814 A5 JP2022529814 A5 JP 2022529814A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- composition according
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1905711.6 | 2019-04-24 | ||
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| PCT/EP2020/061083 WO2020216740A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529814A JP2022529814A (ja) | 2022-06-24 |
| JP2022529814A5 true JP2022529814A5 (enExample) | 2023-04-28 |
| JP7543304B2 JP7543304B2 (ja) | 2024-09-02 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562854A Active JP7543304B2 (ja) | 2019-04-24 | 2020-04-21 | 腎臓病の治療のための新規化合物及びその医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12383544B2 (enExample) |
| EP (1) | EP3958863B1 (enExample) |
| JP (1) | JP7543304B2 (enExample) |
| KR (1) | KR20220004111A (enExample) |
| CN (1) | CN113727711A (enExample) |
| AU (1) | AU2020263869A1 (enExample) |
| BR (1) | BR112021021117A2 (enExample) |
| CA (1) | CA3137445A1 (enExample) |
| ES (1) | ES2982398T3 (enExample) |
| GB (1) | GB201905711D0 (enExample) |
| IL (1) | IL287392A (enExample) |
| MA (1) | MA55752A (enExample) |
| MX (1) | MX2021012544A (enExample) |
| PH (1) | PH12021552680A1 (enExample) |
| SG (1) | SG11202111739VA (enExample) |
| WO (1) | WO2020216740A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096453A1 (en) * | 2023-10-30 | 2025-05-08 | Vertex Pharmaceuticals Incorporated | Compounds for the treatment of kidney disease |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥（香港）有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| EP2464354B1 (en) * | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| TWI633887B (zh) * | 2012-05-31 | 2018-09-01 | 大塚製藥股份有限公司 | 用於預防及／或治療多囊性腎臟病之藥物 |
| US10174012B2 (en) * | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| WO2017060879A1 (en) | 2015-10-09 | 2017-04-13 | AbbVie S.à.r.l. | Novel compounds for treatment of cystic fibrosis |
| PL3359541T3 (pl) * | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| EP3359539A1 (en) | 2015-10-09 | 2018-08-15 | AbbVie S.À.R.L. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| JP2020525446A (ja) * | 2017-06-21 | 2020-08-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子 |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 US US17/605,623 patent/US12383544B2/en active Active
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko not_active Withdrawn
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/en active Active
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
- 2020-04-21 CA CA3137445A patent/CA3137445A1/en active Pending
- 2020-04-21 PH PH1/2021/552680A patent/PH12021552680A1/en unknown
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/en not_active Ceased
- 2020-04-21 JP JP2021562854A patent/JP7543304B2/ja active Active
- 2020-04-21 ES ES20721493T patent/ES2982398T3/es active Active
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021063088A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| CN117597327A (zh) | 药物制剂 | |
| JP2013518107A5 (enExample) | ||
| CA2872121C (en) | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions | |
| JP2024516371A5 (enExample) | ||
| JP2004519469A5 (enExample) | ||
| JP2007533722A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| CN107257786B (zh) | 制备噁噻嗪样化合物的方法 | |
| JP2004516314A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2007524683A5 (enExample) | ||
| CA2656716C (fr) | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique | |
| JP2014508804A5 (enExample) | ||
| JP2009511508A5 (enExample) | ||
| JP2010510237A5 (enExample) | ||
| JP2013541514A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2004500426A5 (enExample) | ||
| JP2020512337A5 (enExample) | ||
| JP2006507220A5 (enExample) | ||
| JP2013519653A5 (enExample) | ||
| WO2021011592A1 (en) | Compounds as nlrp3 inflammasome inhibitors and compositions and uses thereof | |
| JP2006523214A5 (enExample) |